Natera, Inc. (NASDAQ:NTRA) Insider Jonathan Sheena Sells 1,000 Shares

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 1,000 shares of the company’s stock in a transaction on Thursday, April 25th. The shares were sold at an average price of $89.55, for a total transaction of $89,550.00. Following the completion of the sale, the insider now directly owns 69,082 shares in the company, valued at $6,186,293.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jonathan Sheena also recently made the following trade(s):

• On Wednesday, April 3rd, Jonathan Sheena sold 26,700 shares of Natera stock. The stock was sold at an average price of $92.47, for a total value of $2,468,949.00.
• On Thursday, March 28th, Jonathan Sheena sold 447 shares of Natera stock. The shares were sold at an average price of $90.22, for a total value of $40,328.34.
• On Tuesday, March 5th, Jonathan Sheena sold 1,028 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $90,834.08.
• On Tuesday, February 6th, Jonathan Sheena sold 6,000 shares of Natera stock. The shares were sold at an average price of $70.00, for a total transaction of $420,000.00.

Natera Stock Performance

NASDAQ:NTRA opened at $91.66 on Friday. The company’s 50-day moving average is $88.16 and its two-hundred day moving average is $67.50. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $98.82. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The firm has a market capitalization of $11.20 billion, a price-to-earnings ratio of -24.18 and a beta of 1.37.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. The firm had revenue of $311.11 million for the quarter, compared to analysts’ expectations of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. Analysts forecast that Natera, Inc. will post -2.35 EPS for the current year.

Institutional Trading of Natera

A number of hedge funds and other institutional investors have recently modified their holdings of NTRA. RiverPark Advisors LLC purchased a new position in Natera during the fourth quarter worth about $27,000. Principal Securities Inc. purchased a new position in shares of Natera during the 4th quarter worth approximately $32,000. YHB Investment Advisors Inc. purchased a new position in shares of Natera during the 1st quarter worth approximately $36,000. Harvest Fund Management Co. Ltd acquired a new stake in Natera in the 3rd quarter valued at approximately $44,000. Finally, Oliver Lagore Vanvalin Investment Group raised its position in Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 389 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Craig Hallum began coverage on shares of Natera in a report on Monday, April 8th. They issued a “buy” rating and a $117.00 price objective for the company. Raymond James lowered Natera from a “strong-buy” rating to an “outperform” rating and lifted their price target for the company from $68.00 to $85.00 in a research note on Tuesday, February 20th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research report on Tuesday, April 23rd. The Goldman Sachs Group lifted their price target on shares of Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, April 15th. Finally, Stephens reiterated an “overweight” rating and issued a $78.00 price objective on shares of Natera in a report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $86.40.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.